H1's $40M from CVS Says the Quiet Part: Vertical SaaS Is Still Fundable

What happened

H1, a healthcare data platform that connects patients to physicians using an AI-driven matching engine, raised $40 million from CVS Health Ventures. The round is notable less for the dollar amount than for who wrote the check — a strategic corporate investor in one of the most consolidated healthcare payer-provider stacks in the U.S.

"H1 is a nine-year-old healthcare data platform focused on connecting people to the right doctor with an AI-powered platform"

— TechCrunch

Why it matters for SaaS buyers/founders

The fundraising narrative for most of 2026 has been that generalist SaaS is uninvestable and only foundation-model labs can raise real money. H1's round complicates that picture. Nine-year-old vertical software companies with proprietary datasets and enterprise distribution are still closing meaningful strategic rounds — they're just not making the front page of the tech press.

For founders, the takeaway is that the pattern-matching still works: pick a hard vertical, accumulate proprietary data over a long enough time horizon that competitors can't catch up, and layer AI on top. That formula did not die when horizontal SaaS multiples got cut. If anything, it got more valuable, because the AI layer is now cheap and the moat is entirely in the data.

Our take

The more interesting angle is the CVS Health Ventures signal. Strategic corporate rounds in healthcare software are typically about locking in a preferred supplier or preempting a competitor. Either way, they're a signal that a large incumbent has decided the target category is going to matter for their own core business — which is a very different kind of validation than a generalist VC putting in a growth check.

Expect more of these deals over the next few quarters, and expect the winning startups to look nothing like the ones that dominated 2021's cycle. They'll be older, narrower, and less exciting on the surface. But the ones that clear the bar for corporate-strategic capital are the ones most likely to survive whatever the next repricing turns out to be.